Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors
- PMID: 12620807
- DOI: 10.1016/s0042-6822(02)00042-9
Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors
Abstract
L-chicoric acid (L-CA) is a potent inhibitor of HIV integrase (IN) in vitro. In this report, the effects of a glycine to serine mutation at position 140 (G140S) on HIV IN and its effects on IN inhibitor resistance are described. HIV containing the G140S mutation showed a delay in replication. Using real-time polymerase chain reaction, the delay was secondary to a failure in integration. The mutant protein (IN(G140S)) was attenuated approximately four-fold for catalysis under equilibrium conditions compared to wild-type IN (IN(WT)) and attenuated five-fold in steady-state kinetic analysis of disintegration. Fifty percent inhibitory concentration assays were performed with IN inhibitors against both IN proteins in disintegration and strand transfer reactions. IN(G140S) was resistant to both L-CA and L-731,988, a diketoacid. HIV containing the mutation was resistant to both inhibitors as well. The G140S mutation attenuates IN activity and confers resistance to IN inhibitors, suggesting that diketoacids and L-CA interact with a similar binding site on HIV IN.
Similar articles
-
Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.J Virol. 2004 Jun;78(11):5835-47. doi: 10.1128/JVI.78.11.5835-5847.2004. J Virol. 2004. PMID: 15140981 Free PMC article.
-
L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro.Virology. 2004 Sep 1;326(2):203-19. doi: 10.1016/j.virol.2004.06.005. Virology. 2004. PMID: 15302207
-
Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.Mol Pharmacol. 2000 Sep;58(3):641-8. doi: 10.1124/mol.58.3.641. Mol Pharmacol. 2000. PMID: 10953059
-
HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial.Curr Top Med Chem. 2004;4(10):1059-77. doi: 10.2174/1568026043388394. Curr Top Med Chem. 2004. PMID: 15193139 Review.
-
Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.Curr Med Chem. 2003 Sep;10(18):1795-810. doi: 10.2174/0929867033456981. Curr Med Chem. 2003. PMID: 12871105 Review.
Cited by
-
Resistance to integrase inhibitors.Viruses. 2010 Jun 25;2(7):1347-66. doi: 10.3390/v2071347. Viruses. 2010. PMID: 20706558 Free PMC article.
-
Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry.Proc Natl Acad Sci U S A. 2004 May 4;101(18):6894-9. doi: 10.1073/pnas.0400873101. Epub 2004 Apr 26. Proc Natl Acad Sci U S A. 2004. PMID: 15118107 Free PMC article.
-
Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors.Antimicrob Agents Chemother. 2006 Jan;50(1):134-42. doi: 10.1128/AAC.50.1.134-142.2006. Antimicrob Agents Chemother. 2006. PMID: 16377678 Free PMC article.
-
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. doi: 10.1128/AAC.01228-07. Epub 2008 Jan 28. Antimicrob Agents Chemother. 2008. PMID: 18227187 Free PMC article.
-
Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.Biochemistry. 2010 May 4;49(17):3715-22. doi: 10.1021/bi100130f. Biochemistry. 2010. PMID: 20334344 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials